We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Promising Biomarker Discovered for Esophageal Cancer

By LabMedica International staff writers
Posted on 28 May 2014
A new biomarker for esophageal cancer shows promise in improving screening for this deadly disease and its precursor, Barrett's esophagus. More...


Barrett's esophagus (BE) is a leading predictor of esophageal cancer and compared with the general population, patients with BE have an 11-fold higher risk of developing adenocarcinoma of the esophagus.

Scientists at Case Western Reserve University Hospital (Cleveland, OH, USA) examined if a new, non-endoscopic "brushing" of the esophagus is as effective as the more invasive, traditional biopsy. The team based their study on aberrant vimentin methylation, a highly common epigenetic alteration in neoplasia of the upper gastrointestinal tract. They analyzed esophageal specimens in patients with BE, esophageal cancer as well as control subjects. The data determined that methylated vimentin is a highly sensitive biomarker for Barrett's esophagus and that the less invasive brushing technique can effectively detect these changes in the DNA.

Amitabh Chak, MD, who presented the findings, said, “Despite the fact that the rates of common cancers have declined in recent years, esophageal cancer has a poor five-year survival rate of less than 15%. Early detection through screening can prevent the development of esophageal cancer. This promising new test has important clinical implications through its potential to improve screening and decrease mortality from this deadly disease. This is true translational research, bringing a discovery from the laboratory to the patient care setting. This new technique to sensitively detect changes in the DNA may have significant implication for the clinical practice of screening and primary prevention of esophageal cancer.”

Sanford Markowitz, MD, an oncologist at Case Western Reserve University Hospital, said, “Our team's hope is that the use of molecular markers for non-endoscopic screening will drive down the cost and increase the ease of screening for these early esophageal lesions that can give rise to cancer. Longer term we hope to find additional markers that will allow the same approach to be used in the monitoring of Barrett's patients to detect early progression to more advanced disease.” Barrett's esophagus affects up to 6.8% of the population. The study was presented at the Digestive Disease Week (DDW) Annual Meeting held May 3–6, 2014, in Chicago (IL, USA).

Related Links:

Case Western Reserve University Hospital




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.